SJM slides 12% in a month as weak snacks, costly coffee, and tariffs deepen pressure on margins and investor confidence.
Jif peanut butter maker J.M. Smucker said on Thursday it would remove synthetic food colors from all consumer food products by the end of 2027.
ORRVILLE, Ohio , June 26, 2025 /PRNewswire/ -- The J.M. Smucker Co. (NYSE: SJM) today announced its commitment to remove FD&C colors from all consumer food products by the end of calendar year 2027.
Below that level, this key momentum indicator signals that selling pressure has reached extreme levels and can often mark the point where the bears start to run out of steam. For contrarian investors, in particular, these oversold conditions can represent compelling buying opportunities, especially when they occur in established large-cap names.
SJM stock nears its 52-week low as weak pet food and snack sales, rising costs and tariffs pressure margins.
Here are some of the major companies whose stocks moved on the week's news
The J. M. Smucker Company (NYSE:SJM ) Q4 2025 Pre-Recorded Earnings Conference Call June 10, 2025 7:00 AM ET Company Participants Crystal Beiting - Vice President of Investor Relations and FP&A Mark T. Smucker - CEO & Chairman Tucker H.
SJM's fourth-quarter results show mixed performance amid divestitures and acquisitions, with fiscal 2026 outlook guiding soft EPS.
While the top- and bottom-line numbers for Smucker (SJM) give a sense of how the business performed in the quarter ended April 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
The J. M. Smucker Company (NYSE:SJM ) Q4 2025 Earnings Conference Call June 10, 2025 9:00 AM ET Company Participants Crystal Beiting - Vice President of Investor Relations and FPandA Mark T. Smucker - CEO and Chairman Tucker H.
Food and beverage stock J.M.
The J. M. Smucker Company delivered a modest Q4 beat thanks to cost cuts, but sales growth was very disappointing. Higher coffee prices, increased pet food competition, and pressures from GLP-1 drugs will make the next 12 months difficult, and guidance appears too optimistic. At over 12x earnings, shares are not compelling, and I expect SJM to be dead money. Investors should look elsewhere for better opportunities.